Tysabri Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Alerts
• Clinical Trials

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab
Conditions:   Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting Intervention:   Drug: Dosing Interruption of Natalizumab Sponsors:   Berkovich, Regina MD, PhD Inc.;   Biogen;   Cedars-Sinai Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 7, 2019 Category: Research Source Type: clinical trials